ATOS SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 25, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Atossa Therapeutics Executes Contingent Value Rights Agreement for Priority Review Voucher Value

Oct 9, 2026

8-K

Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher

Sep 29, 2026

8-K

Atossa Therapeutics Highlights (Z)-Endoxifen Clinical Pipeline and Financial Position in September 2026 Presentation

Sep 18, 2026

8-K

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Aug 7, 2026

8-K

Atossa Therapeutics Announces $4.5 Million Registered Direct Offering

Jun 11, 2026

8-K

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Corporate Update

May 8, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Jun 12, 2026

424B5

February 2026 ATM | Offering amount: $50,000,000 | Bank: Rodman & Renshaw LLC

Feb 20, 2026

424B3

February 2026 ATM | Bank: Jefferies LLC

Feb 20, 2026

424B5

ATM | Offering amount: $100,000,000

Nov 19, 2024

424B5

17,361,100 Shares of Common Stock-

Mar 23, 2021

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

Feb 4, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 26, 2025

S-3

SHELF | Offering amount: $100,000,000.00 EFFECTIVE

May 13, 2024

S-3

SHARE RESALE REGISTRATION | Shares amount: 13,020,825 | Share price: $2.88 | Warrants amount: 13,020,825 | Warrants exercise price: $2.88 EFFECTIVE

Apr 21, 2021

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 31, 2021

S-3MEF

$8,365,470-

Mar 22, 2021

S-3

10,500,000 Shares- EFFECTIVE

Jan 22, 2021

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 30, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 20, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Dec 22, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Dec 12, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 26, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

May 23, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Steinhart Richard I (Reporting)

May 14, 2026

Chen Shu-Chih (Reporting)

May 14, 2026

Remmel H. Lawrence (Reporting)

May 14, 2026

Finn Jonathan (Reporting)

May 14, 2026

Galli Stephen J (Reporting)

May 14, 2026

Cigler Tessa (Reporting)

May 14, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

May 24, 2024

CORRESP

Form CORRESP - Correspondence

May 21, 2024

LETTER

Form UPLOAD - SEC-generated letter

May 21, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 30, 2021

CORRESP

Form CORRESP - Correspondence

Apr 27, 2021

LETTER

Form UPLOAD - SEC-generated letter

Apr 26, 2021

Atossa Therapeutics, Inc. ATOS · SEC Filings